Evidence map›Paper›PMID 33035235›Full record

ArticlePloS one2020

Two-step mixed model approach to analyzing differential alternative RNA splicing.

Li Luo, Huining Kang, Xichen Li, Scott A Ness, Christine A Stidley

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Li LuoDepartment of Internal Medicine, University of New Mexico, Albuquerque, New Mexico.
Huining KangDepartment of Internal Medicine, University of New Mexico, Albuquerque, New Mexico.ORCID 0000-0002-4415-3573
Xichen LiDepartment of Mathematics and Statistics, University of New Mexico, Albuquerque, New Mexico.
Scott A NessDepartment of Internal Medicine, University of New Mexico, Albuquerque, New Mexico.
Christine A StidleyDepartment of Internal Medicine, University of New Mexico, Albuquerque, New Mexico.

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Mutations and Target Genes in Adenoid Cystic CarcinomaR01DE023222 · NIDCR · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Viswanathan Palanisamy · 2012 to 2026
$5.6M
Alternative RNA splicing and protein products in leukemia outcome (PQ11)R01CA170250 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI NESS, SCOTT A. · 2012 to 2015
$2.3M
NCI NIH HHS P30 CA118100NCI NIH HHS R01 CA170250NIDCR NIH HHS R01 DE023222
6 · The paper itself

Abstract

Changes in gene expression can correlate with poor disease outcomes in two ways: through changes in relative transcript levels or through alternative RNA splicing leading to changes in relative abundance of individual transcript isoforms. The objective of this research is to develop new statistical methods in detecting and analyzing both differentially expressed and spliced isoforms, which appropriately account for the dependence between isoforms and multiple testing corrections for the multi-dimensional structure of at both the gene- and isoform- level. We developed a linear mixed effects model-based approach for analyzing the complex alternative RNA splicing regulation patterns detected by whole-transcriptome RNA-sequencing technologies. This approach thoroughly characterizes and differentiates three types of genes related to alternative RNA splicing events with distinct differential expression/splicing patterns. We applied the concept of appropriately controlling for the gene-level overall false discovery rate (OFDR) in this multi-dimensional alternative RNA splicing analysis utilizing a two-step hierarchical hypothesis testing framework. In the initial screening test we identify genes that have differentially expressed or spliced isoforms; in the subsequent confirmatory testing stage we examine only the isoforms for genes that have passed the screening tests. Comparisons with other methods through application to a whole transcriptome RNA-Seq study of adenoid cystic carcinoma and extensive simulation studies have demonstrated the advantages and improved performances of our method. Our proposed method appropriately controls the gene-level OFDR, maintains statistical power, and is flexible to incorporate advanced experimental designs.

Indexed as

Alternative SplicingGene Regulatory NetworksAlgorithmsCarcinoma, Adenoid CysticChildExome SequencingGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLeukemia, Myeloid, AcuteLinear ModelsModels, GeneticRNA, MessengerSequence Analysis, RNARNA, Messenger

Identifiers

PMID33035235
PMCPMC7546511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.